Advanced Cell Technology Announces Collaboration with the Casey Eye Institute at Oregon Health and Science University.

ALAMEDA, Calif. -- Advanced Cell Technology, Inc. (OTCBB:ACTC) today announced that it has entered into a sponsored research agreement with Oregon Health and Science University. The Company is collaborating with Dr. Raymond Lund, Dr. Richard Weleber and Dr. Peter Francis at the Casey Eye Institute to conduct preclinical studies for its Retinal Pigment Epithelium ("RPE") Program. Specifically, the research team is conducting a dosage study utilizing the Company's RPE cells in the Royal College of Surgeons ("RCS") rat model and plans to conduct similar studies in other rodent models of retinal degenerative disease. The Company is also in discussions with the Oregon Health and Science University team in regard to future plans for a Phase I human clinical trial.

Dr. Peter Francis, Assistant Professor of Ophthalmic Genetics and Co-Director of the Oregon Retinal Degeneration Center at the Casey Eye Institute said, "We are very excited to be working with Advanced Cell Technology. This area or research shows great promise for the treatment of a number of blinding conditions."

Mr. William Caldwell, IV, Chairman and CEO of Advanced Cell Technology responded, "We are very excited to be working with the entire team at the Casey Eye Institute. Drs. Lund, Weleber and Francis bring a wealth of experience to our program in the area of retinal degenerative disease. We are also honored to enter into our first collaboration with Oregon Health and Science University, which has clearly distinguished itself as a leader in biomedical research."

About Advanced Cell Technology, Inc.

Advanced Cell Technology, Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts.

Forward-Looking Statements

Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended September 30, 2006.

Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.